Study Summary
This single-arm, open-label phase I trial evaluates the safety and tolerability of ICG415, autologous CAR-T cells targeting CD33 and CLL1, in patients with relapsed or refractory acute myeloid leukemia (AML). Subjects receive lymphodepleting chemotherapy followed by autologous CAR-T infusion. The primary goal is to assess safety and preliminary anti-leukemic efficacy in patients failing standard AML therapies.
Interested in this trial?
Submit an InquiryInterventions
Anti-CD33-CLL1 CAR-T cells (ICG415) following lymphodepleting fludarabine and cyclophosphamideBIOLOGICAL
Anti-CD33, Anti-CLL1 Compound CAR-T Cells
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Jiangxi Provincial People's Hospital (Participating Site) | Nanchang | Jiangxi | China |
| The First Affiliated Hospital of Nanchang University (Lead Site) | Nanchang | Jiangxi | China |